Abstract
Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.
MeSH terms
-
Animals
-
Carrier Proteins / adverse effects*
-
Carrier Proteins / chemical synthesis
-
Carrier Proteins / metabolism
-
Carrier Proteins / pharmacokinetics
-
Carrier Proteins / pharmacology
-
Carrier Proteins / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Quantitative Structure-Activity Relationship
-
Receptors, Fc / metabolism
-
Receptors, Fc / therapeutic use*
-
Recombinant Fusion Proteins
-
Thrombocytopenia / drug therapy*
-
Thrombopoietin
Substances
-
Carrier Proteins
-
Receptors, Fc
-
Recombinant Fusion Proteins
-
Thrombopoietin
-
romiplostim